October 18, 2021

Gilead’s Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide) has received an expanded indication to treat HIV-1 in children who weigh 14kg (31 pounds) to less than 25kg (55 pounds) and are either virologically suppressed or new to antiretroviral therapy. The FDA also approved a new, lower dosage form of the drug for use in this patient population.

  • Originally FDA approved in 2018 to treat adults, Biktarvy has been approved since 2019 to treat children who weigh at least
  • The new lower dosage form is an oral tablet that offers a complete antiviral treatment regimen. It contains 30mg of bictegravir, 120mg of emtricitabine, and 15mg of tenofovir alafenamide. Recommended dosing is one tablet daily for children weighing 14kg to
  • Adults and children who weigh at least 25kg should take the higher dosage form tablet once It contains 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.
November 19, 2021

COVID-19 Booster Shots Authorized for All Adults

Read More
November 18, 2021

New Warning Added to Climara Pro Prescribing Information

Read More
November 15, 2021

Besremi Approved for Rare Cancer

Read More
November 15, 2021

Mvasi Receives New Cancer Indication

Read More